Deep roots

Regeneron Pharmaceuticals Inc. is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project, the partners have waded through data from over 50,000 patients and found clues about new molecules to target, actionable biomarkers and indications to pursue.

The big questions are how the partners can most efficiently turn that data trove into diagnoses, and whether other institutions will be able to collect similar data for more diverse populations...